{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:53:26Z","timestamp":1785855206016,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"am","delay-in-days":296,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jad.2024.01.119","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T15:47:05Z","timestamp":1705592825000},"page":"452-467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Drug-induced depressive symptoms: An update through the WHO pharmacovigilance database"],"prefix":"10.1016","volume":"350","author":[{"given":"Julien","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Zelmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"Storck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard-Jules","family":"Laforgue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Yrondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Balcerac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Sommet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.01.119_bb0005","unstructured":"Adverse Reactions Search Results - MICROMEDEX [WWW Document], n.d. URL https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/CS\/C21ACF\/ND_PR\/evidencexpert\/ND_P\/evidencexpert\/DUPLICATIONSHIELDSYNC\/6D457D\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_AppProduct\/evidencexpert\/ND_T\/evidencexpert\/PFActionId\/evidencexpert.DoIntegratedSearch?SearchTerm=drugs%20that%20cause%20depression&UserSearchTerm=drugs%20that%20cause%20depression&SearchFilter=filterNone&navitem=searchALL (accessed 6.26.23)."},{"key":"10.1016\/j.jad.2024.01.119_bb0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neuron.2020.06.002","article-title":"The bidirectional relationship of depression and inflammation: double trouble","volume":"107","author":"Beurel","year":"2020","journal-title":"Neuron"},{"key":"10.1016\/j.jad.2024.01.119_bb0015","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapies"},{"key":"10.1016\/j.jad.2024.01.119_bb0020","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.yebeh.2019.01.022","article-title":"Epilepsy, depression and growth hormone","volume":"94","author":"Butler","year":"2019","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.jad.2024.01.119_bb0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.31887\/DCNS.2011.13.1\/ccelano","article-title":"Depressogenic effects of medications: a review","volume":"13","author":"Celano","year":"2011","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.jad.2024.01.119_bb0030","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3348\/kjr.2018.0356","article-title":"Gadolinium deposition in the brain: current updates","volume":"20","author":"Choi","year":"2019","journal-title":"Korean J. Radiol."},{"key":"10.1016\/j.jad.2024.01.119_bb0035","unstructured":"Depression [WWW Document], n.d. URL https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression (accessed 3.29.23)."},{"key":"10.1016\/j.jad.2024.01.119_bb0040","unstructured":"Diagnostic and statistical manual of mental disorders: DSM-5TM, 5th ed., n.d."},{"key":"10.1016\/j.jad.2024.01.119_bb0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case\u2013non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapies, PHARMACOEPIDEMIOLOGY"},{"key":"10.1016\/j.jad.2024.01.119_bb0050","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2024.01.119_bb0055","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.drudis.2008.12.012","article-title":"Decision support methods for the detection of adverse events in post-marketing data","volume":"14","author":"Hauben","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jad.2024.01.119_bb0060","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1111\/bcp.15436","article-title":"Identifying new drugs associated with pulmonary arterial hypertension: a WHO pharmacovigilance database disproportionality analysis","volume":"88","author":"Hlavaty","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2024.01.119_bb0065","unstructured":"Isotr\u00e9tino\u00efne et effets psychiatriques - ANSM: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 [WWW Document], n.d. URL https:\/\/archiveansm.integra.fr\/S-informer\/Communiques-Communiques-Points-presse\/Isotretinoine-et-effets-psychiatriques (accessed 5.26.23)."},{"key":"10.1016\/j.jad.2024.01.119_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-03214-x","article-title":"Common osteoporosis drug associated with increased rates of depression and anxiety","volume":"11","author":"Keshishi","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jad.2024.01.119_bb0075","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jclinepi.2021.01.015","article-title":"Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases","volume":"134","author":"Khouri","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jad.2024.01.119_bb0080","first-page":"162","article-title":"Depression trends in hepatitis-C PCR positive and PCR negative patients","volume":"38","author":"Khuhro","year":"2022","journal-title":"Pak. J. Med. Sci."},{"key":"10.1016\/j.jad.2024.01.119_bb0085","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2515\/therapie\/2015026","article-title":"Drug-induced depression: a case\/non case study in the French pharmacovigilance database","volume":"70","author":"Lafay-Chebassier","year":"2015","journal-title":"Therapies"},{"key":"10.1016\/j.jad.2024.01.119_bb0090","article-title":"Use of isotretinoin and risk of depression in patients with acne: a systematic review and meta-analysis","volume":"9","author":"Li","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jad.2024.01.119_bb0095","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00002018-200730070-00009","article-title":"Standardised MedDRA queries: their role in signal detection","volume":"30","author":"Mozzicato","year":"2007","journal-title":"Drug Saf."},{"key":"10.1016\/j.jad.2024.01.119_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222037","article-title":"Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts","volume":"2017","author":"Petrous","year":"2017","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.jad.2024.01.119_bb0105","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1001\/jama.2018.6741","article-title":"Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States","volume":"319","author":"Qato","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2024.01.119_bb0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4088\/JCP.v66n0106","article-title":"Depression during Pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction","volume":"66","author":"Raison","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.119_bb0115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jad.2017.06.009","article-title":"Multimorbidity and depression: a systematic review and meta-analysis","volume":"221","author":"Read","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.01.119_bb0120","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jad.2024.01.119_bb0125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.maturitas.2016.09.004","article-title":"Depression in midlife women","volume":"94","author":"Sassarini","year":"2016","journal-title":"Maturitas"},{"key":"10.1016\/j.jad.2024.01.119_bb0130","series-title":"International Review of Neurobiology, Nonmotor Parkinson\u2019s: The Hidden Face","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/bs.irn.2017.05.024","article-title":"Chapter twenty - depression and anxiety in Parkinson\u2019s disease","author":"Schrag","year":"2017"},{"key":"10.1016\/j.jad.2024.01.119_bb0135","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/515180a","article-title":"Mental health: a world of depression","volume":"515","author":"Smith","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jad.2024.01.119_bb0140","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1055\/s-2008-1078744","article-title":"Rimonabant and depression","volume":"41","author":"Soyka","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jad.2024.01.119_bb0145","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.psym.2017.04.001","article-title":"Cystic fibrosis transmembrane regulator modulators: implications for the management of depression and anxiety in cystic fibrosis","volume":"58","author":"Talwalkar","year":"2017","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jad.2024.01.119_bb0150","unstructured":"Taylor, D.M., Barnes, T., Young, A., H., n.d. The Maudsley prescribing guidelines in psychiatry (13th ed.)."},{"key":"10.1016\/j.jad.2024.01.119_bb0155","doi-asserted-by":"crossref","first-page":"9260","DOI":"10.4088\/JCP.12r07694","article-title":"Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis","volume":"73","author":"Udina","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.119_bb0160","doi-asserted-by":"crossref","DOI":"10.1111\/j.1469-1809.1955.tb01348.x","article-title":"On estimating the relation between blood group and disease","volume":"19","author":"Woolf","year":"1955","journal-title":"Ann. Hum. Genet."},{"key":"10.1016\/j.jad.2024.01.119_bb0165","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1111\/jcmm.14390","article-title":"The exploration of mechanisms of comorbidity between migraine and depression","volume":"23","author":"Zhang","year":"2019","journal-title":"J. Cell. Mol. Med."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724001290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724001290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:48:46Z","timestamp":1762789726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724001290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":33,"alternative-id":["S0165032724001290"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.01.119","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced depressive symptoms: An update through the WHO pharmacovigilance database","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.01.119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}